APA

Naing A., Meric-Bernstam F., Stephen B., Karp D. D., Hajjar J., Rodon Ahnert J., Piha-Paul S. A., Colen R. R., Jimenez C., Raghav K. P., Ferrarotto R., Tu S., Campbell M., Wang L., Sabir S. H., Tapia C., Bernatchez C., Frumovitz M., Tannir N., Ravi V., Khan S., Painter J. M., Abonofal A., Gong J., Alshawa A., McQuinn L. M., Xu M., Ahmed S., Subbiah V., Hong D. S., Pant S., Yap T. A., Tsimberidou A. M., Dumbrava E. E. I., Janku F., Fu S., Simon R. M., Hess K. R., Varadhachary G. R. & Habra M. A. (20210608). Phase 2 study of pembrolizumab in patients with advanced rare cancers. : Journal for immunotherapy of cancer.

Chicago

Naing Aung, Meric-Bernstam Funda, Stephen Bettzy, Karp Daniel D, Hajjar Joud, Rodon Ahnert Jordi, Piha-Paul Sarina A, Colen Rivka R, Jimenez Camilo, Raghav Kanwal P, Ferrarotto Renata, Tu Shi-Ming, Campbell Matthew, Wang Linghua, Sabir Sarjeel H, Tapia Coya, Bernatchez Chantale, Frumovitz Michael, Tannir Nizar, Ravi Vinod, Khan Saria, Painter Jeane M, Abonofal Abulrahman, Gong Jing, Alshawa Anas, McQuinn Lacey M, Xu Mingxuan, Ahmed Sara, Subbiah Vivek, Hong David S, Pant Shubham, Yap Timothy A, Tsimberidou Apostolia M, Dumbrava Ecaterina E Ileana, Janku Filip, Fu Siqing, Simon Richard M, Hess Kenneth R, Varadhachary Gauri R and Habra Mouhammed Amir. 20210608. Phase 2 study of pembrolizumab in patients with advanced rare cancers. : Journal for immunotherapy of cancer.

Harvard

Naing A., Meric-Bernstam F., Stephen B., Karp D. D., Hajjar J., Rodon Ahnert J., Piha-Paul S. A., Colen R. R., Jimenez C., Raghav K. P., Ferrarotto R., Tu S., Campbell M., Wang L., Sabir S. H., Tapia C., Bernatchez C., Frumovitz M., Tannir N., Ravi V., Khan S., Painter J. M., Abonofal A., Gong J., Alshawa A., McQuinn L. M., Xu M., Ahmed S., Subbiah V., Hong D. S., Pant S., Yap T. A., Tsimberidou A. M., Dumbrava E. E. I., Janku F., Fu S., Simon R. M., Hess K. R., Varadhachary G. R. and Habra M. A. (20210608). Phase 2 study of pembrolizumab in patients with advanced rare cancers. : Journal for immunotherapy of cancer.

MLA

Naing Aung, Meric-Bernstam Funda, Stephen Bettzy, Karp Daniel D, Hajjar Joud, Rodon Ahnert Jordi, Piha-Paul Sarina A, Colen Rivka R, Jimenez Camilo, Raghav Kanwal P, Ferrarotto Renata, Tu Shi-Ming, Campbell Matthew, Wang Linghua, Sabir Sarjeel H, Tapia Coya, Bernatchez Chantale, Frumovitz Michael, Tannir Nizar, Ravi Vinod, Khan Saria, Painter Jeane M, Abonofal Abulrahman, Gong Jing, Alshawa Anas, McQuinn Lacey M, Xu Mingxuan, Ahmed Sara, Subbiah Vivek, Hong David S, Pant Shubham, Yap Timothy A, Tsimberidou Apostolia M, Dumbrava Ecaterina E Ileana, Janku Filip, Fu Siqing, Simon Richard M, Hess Kenneth R, Varadhachary Gauri R and Habra Mouhammed Amir. Phase 2 study of pembrolizumab in patients with advanced rare cancers. : Journal for immunotherapy of cancer. 20210608.